TKD Stock Overview
Engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Takeda Pharmaceutical Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥24.26 |
| 52 Week High | JP¥30.99 |
| 52 Week Low | JP¥23.37 |
| Beta | 0.51 |
| 11 Month Change | 0.41% |
| 3 Month Change | -5.64% |
| 1 Year Change | -14.70% |
| 33 Year Change | -14.09% |
| 5 Year Change | -22.55% |
| Change since IPO | -12.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| TKD | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 2.9% | -4.8% | 0.8% |
| 1Y | -14.7% | -19.4% | 2.0% |
Return vs Industry: TKD exceeded the German Pharmaceuticals industry which returned -19.4% over the past year.
Return vs Market: TKD underperformed the German Market which returned 2% over the past year.
Price Volatility
| TKD volatility | |
|---|---|
| TKD Average Weekly Movement | 2.6% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: TKD has not had significant price volatility in the past 3 months.
Volatility Over Time: TKD's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1781 | 49,095 | Christophe Weber | www.takeda.com |
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands.
Takeda Pharmaceutical Company Limited Fundamentals Summary
| TKD fundamental statistics | |
|---|---|
| Market cap | €37.99b |
| Earnings (TTM) | €836.02m |
| Revenue (TTM) | €24.74b |
45.4x
P/E Ratio1.5x
P/S RatioIs TKD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TKD income statement (TTM) | |
|---|---|
| Revenue | JP¥4.26t |
| Cost of Revenue | JP¥1.43t |
| Gross Profit | JP¥2.84t |
| Other Expenses | JP¥2.69t |
| Earnings | JP¥144.07b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 31, 2024
| Earnings per share (EPS) | 91.82 |
| Gross Margin | 66.54% |
| Net Profit Margin | 3.38% |
| Debt/Equity Ratio | 66.6% |
How did TKD perform over the long term?
See historical performance and comparison